The Kenneth Rainin Foundation Announces $100,000 Innovator Awards Program for Inflammatory Bowel Disease (IBD) Research

/PRNewswire/ -- The Kenneth Rainin Foundation announced today its new Innovator Awards Program for Inflammatory Bowel Disease. The Program is designed to accelerate the pace of discovery in IBD research. Approximately four million people worldwide suffer from some form of IBD and most are diagnosed between the ages of 20 and 40.

"Launching the Kenneth Rainin Foundation's Innovator Awards Program for IBD research is very exciting for all of us," said Jen Rainin, president of the Kenneth Rainin Foundation. "Our Program is unique in that it encourages investigators from all scientific disciplines and from any non-profit research institution to collaborate to explore bold and innovative ideas that can expand our understanding of IBD, which, in turn, will have a major impact in finding a cure for IBD."

Jen Rainin is the daughter of the late founder, Kenneth Rainin, who suffered greatly from IBD. To further his memory and accomplish the Foundation's mission of no one suffering from IBD, the Innovator Awards Program is focused on finding applicants with diverse backgrounds who can help build a creative, conceptual paradigm for IBD with emphasis on the importance of nurturing interdisciplinary collaboration between fields. Alternative approaches that are nutrition-based or holistic in nature may also play an important role in our research.

Initial one-year grants of $100,000 will be awarded once annually. The first round of applications will be accepted February 15 - March 15, 2010. Applications must be submitted online, and selected applicants will be notified in July, 2010. Applications will be initially reviewed by our Scientific Advisory Board. Based on their recommendations, final selections will be made by the Foundation's Board. Successful projects will be eligible for significant multi-year funding based on the initial year's proof of principle work.

About Inflammatory Bowel Disease

Inflammatory bowel disease (IBD) is a group of inflammatory conditions of the gastrointestinal tract. The main forms of IBD are Crohn's Disease and ulcerative colitis. Symptoms include pain, bleeding and debilitation. Current therapeutic options for patients are largely limited to the use of anti-inflammatory steroids applied either systemically or locally for the treatment of the symptoms. Removal of the colon is the only cure at this time.

-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page

Arthritis Foundation Announces Top 10 Arthritis Advances of 2007

PRNewswire-USNewswire/ -- A team of engineers have recently created a new framework upon which cartilage tissue can be grown. The novel scaffold is porous, so the fabric can be seeded with cells and transplanted into a joint damaged by arthritis. The woven "fabric" will be absorbed by the body, leaving only healthy, strong cartilage for those who suffer from osteoarthritis or other cartilage injuries. This is just one of the top 10 most significant arthritis advances of 2007, according to the Arthritis Foundation.

The Arthritis Foundation's annual Top 10 Arthritis Advances also includes a survey released by the Centers for Disease Control and Prevention (CDC) quantifying the high cost of arthritis, in which arthritis-attributable work limitation affects one in three working-age adults (aged 18-64 years) with doctor-diagnosed arthritis. Another important advance this past year was the first ever quantification of the number of children with juvenile arthritis and documentation of the severe shortage of pediatric rheumatologists to provide diagnosis and care for children with juvenile arthritis in the United States. Moreover, several approaches were identified to increase access to subspecialty care by pediatric rheumatologists, which include enhancing the availability and financing of fellowship training to increase the number of trainees in the field and also improving the financial viability of pediatric rheumatology practices in academic settings.

"As the prevalence of arthritis continues to soar in the United States, advances made in 2007 provide the groundwork for improving the lives of the 46 millions people who live with arthritis now and the 40% more projected to be affected by 2030," said John H. Klippel, M.D., president and CEO of the Arthritis Foundation. "With arthritis being the most common cause of disability, advances in research and the development of more effective and safer treatments will continue to contribute in helping to improve the quality of life for people with arthritis."

The Arthritis Foundation's Top 10 Arthritis Events of 2007 include:
-- Passage of FDA Legislation on Drug Regulation and Safety
-- Quantification of Work Limitation and Earnings Losses

-- Projections of Increases in Doctor-Diagnosed Arthritis and Arthritis-Attributable Activity Limitation

-- Identification of RA Susceptibility Genes STAT4 and TRAF1-C5
-- Uncovering the Importance of Cadherin-11
-- Development of a Woven Mesh for Cartilage Engineering
-- Approval of Lyrica for Treatment of Fibromyalgia
-- Availability of NIH's Osteoarthritis Data and Images
-- Quantification of Children with Arthritis and Number of Doctors Needed
-- Evidence of Benefit and Safety of Biologic Therapy in Children

Summaries of each of the top arthritis advances, as well as what they mean for arthritis patients are available at http://www.arthritis.org/top-10-2007.php

To develop its fifth annual list of the Top 10 Arthritis Advances, the Arthritis Foundation sought input from clinicians with expertise in various forms of arthritis, scientists from a wide variety of research disciplines, and organizations with an interest in arthritis and related diseases.